Basics of particle therapy II biologic and dosimetric aspects of clinical hadron therapy
- PMID: 20395789
- DOI: 10.1097/COC.0b013e3181cdf0fe
Basics of particle therapy II biologic and dosimetric aspects of clinical hadron therapy
Abstract
Besides photons and electrons, high-energy particles like protons, neutrons, ⁴He ions or heavier ions (C, Ne, etc) have been finding increasing applications in the treatment of radioresistant tumors and tumors located near critical structures. The main difference between photons and hadrons is their different biologic effect and depth-dose distribution. Generally speaking, protons are superior in dosimetric aspects whereas neutrons have advantages in biologic effectiveness because of the high linear energy transfer. In 1946 Robert Wilson first published the physical advantages in dose distribution of ion particles for cancer therapy. Since that time hadronic radiotherapy has been intensively studied in physics laboratories worldwide and clinical application have gradually come to fruition. Hadron therapy was made possible by the advances in accelerator technology, which increases the particles' energy high enough to place them at any depth within the patient's body. As a follow-up to the previous article Introduction to Hadrons, this review discusses certain biologic and dosimetric aspects of using protons, neutrons, and heavy charged particles for radiation therapy.
Similar articles
-
Basics of particle therapy: introduction to hadrons.Am J Clin Oncol. 2008 Oct;31(5):493-5. doi: 10.1097/COC.0b013e31816a6237. Am J Clin Oncol. 2008. PMID: 18838888 Review.
-
The clinical experience with particle therapy in adults.Cancer J. 2009 Jul-Aug;15(4):306-11. doi: 10.1097/PPO.0b013e3181b01922. Cancer J. 2009. PMID: 19672147 Review.
-
Medical physics aspects of particle therapy.Radiat Prot Dosimetry. 2009 Nov;137(1-2):156-66. doi: 10.1093/rpd/ncp192. Epub 2009 Oct 14. Radiat Prot Dosimetry. 2009. PMID: 19828718
-
Particle radiation therapy using proton and heavier ion beams.J Clin Oncol. 2007 Mar 10;25(8):953-64. doi: 10.1200/JCO.2006.09.7816. J Clin Oncol. 2007. PMID: 17350944 Review.
-
Should positive phase III clinical trial data be required before proton beam therapy is more widely adopted? No.Radiother Oncol. 2008 Feb;86(2):148-53. doi: 10.1016/j.radonc.2007.12.024. Epub 2008 Jan 30. Radiother Oncol. 2008. PMID: 18237800
Cited by
-
Radiation oncology in the era of precision medicine.Nat Rev Cancer. 2016 Apr;16(4):234-49. doi: 10.1038/nrc.2016.18. Epub 2016 Mar 18. Nat Rev Cancer. 2016. PMID: 27009394 Review.
-
Primary adenoid cystic carcinoma of the trachea: clinical outcome of 38 patients after interdisciplinary treatment in a single institution.Radiat Oncol. 2019 Jul 4;14(1):117. doi: 10.1186/s13014-019-1323-z. Radiat Oncol. 2019. PMID: 31272473 Free PMC article. Clinical Trial.
-
Immune modulation and stereotactic radiation: improving local and abscopal responses.Biomed Res Int. 2013;2013:658126. doi: 10.1155/2013/658126. Epub 2013 Nov 14. Biomed Res Int. 2013. PMID: 24324970 Free PMC article. Review.
-
Dose Constraints in Carbon-Ion Radiation Therapy to Minimize the Risk of Pectoral Myositis.Int J Part Ther. 2025 Mar 27;16:100746. doi: 10.1016/j.ijpt.2025.100746. eCollection 2025 Jun. Int J Part Ther. 2025. PMID: 40235851 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials